Medscape July 30, 2024
The first in-human trial of a CRISPR Cas system delivered by adeno-associated virus 9 gene therapy to treat HIV was able to target only the intended DNA and cleared the blood within 6 months.
EBT-101-001 is the first gene therapy administered intravenously designed to attack the latent HIV proviral genome with an adeno-associated virus 9 CRISPR Cas9 multiplex.
The results of the phase 1/2, presented at the International AIDS Conference 2024 are “a first step,” said Rachel Presti, MD, PhD, medical director of the infectious disease clinical research unit at Washington University, St. Louis, Missouri.
“This study is highly unique,” added Chantelle Ahlenstiel, PhD, a senior research fellow in immunovirology and pathogenesis at the Kirby Institute at the University of...
Today's Sponsors
Today's Sponsor